Nivolumab shows promising safety but did not significantly improve survival in liver cancer patients
In short: A phase 3 clinical trial of 743 patients found that nivolumab monotherapy did not significantly improve overall survival compared to sorafenib for those with advanced hepatocellular carcinoma. While the immunotherapy showed a favorable safety profile and clinical activity, it failed to meet the protocol-defined significance level for improving survival in this first-line treatment setting.
Researchers conducted this randomized trial across 22 countries, comparing nivolumab to sorafenib in patients with advanced hepatocellular carcinoma who had not received previous systemic therapy.
While the study observed clinical activity and a manageable safety profile, the primary endpoint of overall survival did not reach statistical significance.
Why it matters: Nivolumab may be a therapeutic option for patients who cannot tolerate tyrosine kinase inhibitors due to safety risks.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Yau et al. (2022). Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. The Lancet. Oncology.
To cite this card, link to https://intellectplus.co.uk/app/health-research-nivolumab-shows-promising-safety-but-did-not-significantly-i.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Health · Latest · A–Z · All topics
